drugset / Trial / NCT03121339
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
RandomizedParallel-groupOpen-labelOther
Summary
This is a phase 1 open-label pharmacodynamics study in healthy adults. The purpose of the study is to determine if the tablet formulation size of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, has an impact on delivery location. The secondary objective is to evaluate delivery with fasting versus fed status.
Timeline
- Start
- 2017-03-31
- Primary completion
- 2017-05-05
- Completion
- 2018-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VXA-A1.1 H1 Tablet Vaccine | Vaccine | 140 mg | Oral |
| Comparator | VXA-A1.1 H1 Tablet Vaccine | Vaccine | 275 mg | Oral |
Indications
No indication recorded.